In line with the justification for multi-targeted approaches in the treatment of lung cancer, for example, combining CDK1 inhibitors with techniques to restore tumor-suppressive miR-143–3p or inhibit oncogenic PVT1 may suppress cell-cycle progression and increase sensitivity to currently available chemotherapies [49]. This evidence concerns the gene PVT1 and lung cancer.